The latestA recall affected losartan (Cozaar), valsartan (Diovan
and Prexxartan) and irbesartan (Avapro).A ARBs are known for helping reduce blood pressure.
Zydus Cadila has received the final approval from the USFDA lo market Valsartan and Hydrochlorothiazide Tablets USP (US RLD - Diovan
HCT Tablets) in the strengths of 80 mg 12.5 mg, 160 mg.
Public health agency the US Food and Drug Administration stated on Tuesday that it has authorised the new generic version of Diovan
(valsartan) for the treatment of high blood pressure and heart failure.
Volume contributed 11 percentage points driven by growth drivers and higher Diovan
and Exforge benefitting from the recall of competitor generic products.
In 2010, valsartan (trade name Diovan
) achieved annual sales of USD 2.052bn in the United Statesand USD 6.053bn worldwide.
She said Diovan
and Co-Diovan, manufactured by Novartis, have not been withdrawn because they are genuine.
Swiss multinational pharmaceutical compaany Novartis informed the ministry that their products containing Valsartan - Diovan
, Co-Diovan Entresto and Exforge - are not impacted because these products do not contain the active ingredient from an external supplier.
Novartis says hypertension medication Diovan
is safe to use
Swiss multinational pharmaceutical company Novartis informed the ministry that their products containing Valsartan -- Diovan
, Co-Diovan Entresto and Exforge -- are not impacted because these products do not contain Valsartan from an external supplier.
The drug classes include angiotensin receptor blockers, such as Novartis AG's Diovan
, calcium channel blockers, like Pfizer Incs's Norvasc, ACE inhibitors, including Pfizer's Altace, and diuretics, such as Merck & Co Inc's Hyzaar.
was discharged from the hospital on a dose of oral prednisone 20 mg twice daily for 10 days and ordered to continue her current medications of Diovan
320 mg daily, HCTZ 12.5 mg daily, atenolol 25 mg daily, Prilosec 20 mg daily, and Humira pen 40 mg every other week.
Comments: Pharmaceutical sales were $7.1 billion in the quarter, down 9%, and included the new oncology assets acquired from GSK (sales of $0.2 billion in March), offset by the negative impact of generic competition, largely for Diovan
, Exforge and Vivelle-Dot in the U.S.